The Protocol Review Committee (PRC) is a multi-disciplinary committee whose mission is to provide scientific review for all clinical protocols involving cancer patients at the University of Iowa Hospitals and Clinics, or UICC resources. This review includes any protocol that: 1) involves patients seen in the John and Marry Pappajohn Clinical Cancer Center or cancer patients from other units in the hospital such as the Bone Marrow Transplantation Unit, Radiation Therapy, the General Clinical Research Center, and the Oncology ward of the Children's Hospital of Iowa or 2) uses UICC resources such as the Core facilities. The role of the PRC is complementary to that of the IRB The PRC is complementary to that of the IRB. The PRC ensures that 1) institutional protocols have adequate scientific rationale to justify the hypothesis, 2) experimental design is rational and includes a clearly stated valid statistical section, a realistic assessment of accrual and appropriate response parameters, 3) the scientific question to be answered is of sufficient interest to justify use of UICC resources, 4) investigators have considered all potential basic science correlates that might be pursued as part of their studies, and 5) studies are prioritized that deal with similar patient populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA086862-01
Application #
6401915
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2000-07-14
Project End
2005-06-30
Budget Start
Budget End
Support Year
1
Fiscal Year
2000
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
041294109
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Kim, Yusung; Cabel, Katherine; Sun, Wenqing (2018) Does the apex optimization line matter for single-channel vaginal cylinder brachytherapy planning? J Appl Clin Med Phys 19:307-312
Hagan, Teresa L; Gilbertson-White, Stephanie; Cohen, Susan M et al. (2018) Symptom Burden and Self-Advocacy: Exploring the Relationship Among Female Cancer Survivors?. Clin J Oncol Nurs 22:E23-E30
Chesney, Jason; Puzanov, Igor; Collichio, Frances et al. (2018) Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol 36:1658-1667
Brooks, Jennifer D; Comen, Elizabeth A; Reiner, Anne S et al. (2018) CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. Breast Cancer Res 20:149
Chioreso, Catherine; Del Vecchio, Natalie; Schweizer, Marin L et al. (2018) Association Between Hospital and Surgeon Volume and Rectal Cancer Surgery Outcomes in Patients With Rectal Cancer Treated Since 2000: Systematic Literature Review and Meta-analysis. Dis Colon Rectum 61:1320-1332
Musselman, Catherine A; Kutateladze, Tatiana G (2018) A histone reader becomes the readout. J Biol Chem 293:7486-7487
Merritt, Nicole M; Fullenkamp, Colleen A; Hall, Sarah L et al. (2018) A comprehensive evaluation of Hippo pathway silencing in sarcomas. Oncotarget 9:31620-31636
Haskins, Cole B; McDowell, Bradley D; Carnahan, Ryan M et al. (2018) Impact of preexisting mental illness on breast cancer endocrine therapy adherence. Breast Cancer Res Treat :
Daneshmand, Siamak; Patel, Sanjay; Lotan, Yair et al. (2018) Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. J Urol 199:1158-1165
Borcherding, Nicholas; Kolb, Ryan; Gullicksrud, Jodi et al. (2018) Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. J Mol Biol 430:2014-2029

Showing the most recent 10 out of 1080 publications